| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-12446SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB500-249SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77299SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 405 | NB110-87318AF405 | |||
| Alexa Fluor 488 | NB110-87318AF488 | |||
| Alexa Fluor 647 | NB110-87318AF647 | |||
| Alexa Fluor 700 | NB110-87318AF700 | |||
| Biotin | NB110-87318B | |||
| DyLight 488 | NB110-87318G | |||
| DyLight 550 | NB110-87318R | |||
| DyLight 650 | NB110-87318C | |||
| HRP | NB110-87318H | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-87318SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22217SS | |||
| Azide and BSA Free | NBP2-80825 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77080SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24588SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-60002SS | |||
| Azide and BSA Free | NBP2-80693 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56152SS | |||
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Western blot analysis of TXNIP & NLRP3 protein expression in cultured HK-2 cells treated by normal glucose (5.5 mM), high glucose (30 mM), & NG + mannitol, respectively, for 72 hours, then following 4 hours of hypoxia & 2 hours of reoxygenation in HK-2 cells under high glucose stimulation with or without TXNIP siRNA & RES treatment, respectively. Representative blots (a) & quantitative analysis of Western blots for TXNIP (c) & NLRP3 (d), activity of caspase-1 (e), level of IL-1 beta (f), & Western blot of TXNIP gene knockdown in HK-2 cells (b). The data in (c–f) are means ± SE (n = 5). #P 0.05; *p 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113536.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Exercise training prevents HFD-induced upregulation of cardiac pyroptosis. Western blotting was performed to determine the components of inflammasome complex & pyroptosis in the left ventricle of mice hearts. (A) HFD-fed obese mice show upregulation of the NLRP3 inflammasome in the left ventricle, which is prevented by exercise training. (B) Apoptosis-associated speck adaptor protein (ASC) that assembles with NLRP3 & caspase-1 to make inflammasome complex is elevated in the heart of obese mice but attenuated by exercise training. (C) Exercise training prevents HFD-induced upregulation of cardiac caspase-1. (D) Expression of IL-1 beta , which is upregulated by HFD, is normalized by exercise training. All values are expressed as mean ± SEM with dots of different shape representing each animal in a group. One-way ANOVA & Tukey’s post-hoc test were used for statistical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31835893), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241612224.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - NLRP3 knockdown decreases corneal inflammation & suppressed neutrophil infiltration in mouse C. albicans keratitis. The C57BL/6 mice were subconjunctivally injected with 6 μL (4 × 108 PFU) of the Ad-GFP-shRNA or Ad-NLRP3-shRNA suspension 3 days before inoculation with 1 × 106 CFU C. albicans or with 5μL sterile PBS after the corneas were scratched. The mouse corneas or eyeballs were collected at 3 dpi & subjected for further detection. RT-qPCR analysis (A), western blot (B) & immunofluorescence staining (C) were used to verify the gene knockdown efficiency of Ad-NLRP3-shRNA (n = 3). Scale bar = 20 μm; magnification 400×. (D) Micrographs of Ad-GFP-shRNA & Ad-NLRP3-shRNA-pretreated mouse corneas were photographed at 3dpi. (E) Clinical score of the infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3-shRNA (n = 10). (F) Immunofluorescence staining was performed to assess the levels of neutrophils recruitment in mouse corneas after Ad-GFP-shRNA & Ad-NLRP3-shRNA pretreatment (n =3). Scale bar = 50 μm; magnification 200×. FK: fungal keratitis. All values are presented as mean ± SEM. **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241613619.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - NLRP3 knockdown decreases corneal inflammation & suppressed neutrophil infiltration in mouse C. albicans keratitis. The C57BL/6 mice were subconjunctivally injected with 6 μL (4 × 108 PFU) of the Ad-GFP-shRNA or Ad-NLRP3-shRNA suspension 3 days before inoculation with 1 × 106 CFU C. albicans or with 5μL sterile PBS after the corneas were scratched. The mouse corneas or eyeballs were collected at 3 dpi & subjected for further detection. RT-qPCR analysis (A), western blot (B) & immunofluorescence staining (C) were used to verify the gene knockdown efficiency of Ad-NLRP3-shRNA (n = 3). Scale bar = 20 μm; magnification 400×. (D) Micrographs of Ad-GFP-shRNA & Ad-NLRP3-shRNA-pretreated mouse corneas were photographed at 3dpi. (E) Clinical score of the infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3-shRNA (n = 10). (F) Immunofluorescence staining was performed to assess the levels of neutrophils recruitment in mouse corneas after Ad-GFP-shRNA & Ad-NLRP3-shRNA pretreatment (n =3). Scale bar = 50 μm; magnification 200×. FK: fungal keratitis. All values are presented as mean ± SEM. **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113526.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Heat-killed C. albicans (HKCA) activates NLRP3 inflammasome & induces pyroptosis in human corneal epithelial cells (HCECs). (A) The mRNA expression of NLRP3 in HCECs challenged with HKCA at an MOI of 1:500, 1:50, 1:5, 2:1, or 20:1 respectively for 4 hours was evaluated by RT-qPCR (n = 5). (B–D) The mRNA & protein expression of NLRP3 in HCECs exposed to HKCA (MOI = 20) for 0 (control), 2, 4, 8, 12, or 24 h (n = 3). (E) NLRP3 fluorescence intensity was evaluated using immunofluorescent staining for different times (12–36 h). (n = 3; Scale bar = 20 μm; magnification 400×). (F) Lactate dehydrogenase (LDH) of HCECs treated with HKCA (MOI = 20) for 24 h (n = 6). (G) The mRNA levels of ASC, CASP1, IL-1 beta , IL-18 & GSDMD in HCECs exposed to HKCA (MOI = 20) for different times (n = 3). (H,I) The protein expression of pyroptosis-related proteins (ASC, cleaved CASP1, N-GSDMD, cleaved IL-1 beta & cleaved IL-18) was examined by western blot (n = 3). CASP1: caspase-1; Clv-CASP1: cleaved CASP1; Clv-IL-1 beta : cleaved IL-1 beta ; Clv-IL-18: cleaved IL-18; N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241611470.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - The P2X7R inhibitor suppressed PA-induced inflammation, fibrosis & apoptosis in cardiomyocytes. (A) Cell viability was assessed by the CCK8 assay. H9c2 myocytes were incubated in a medium with A438079 at 0–80 μM for 12 h, & cells without A438079 treatment served as the control. (B) H9c2 myocytes were incubated in a medium with PA at 0–800 μM for 24 h, & cells without PA treatment served as the control. (C) Concentrations of IL-1 beta in cell culture supernatants were detected by ELISA. (D) Representative Western blot analysis of P2X7R, NLRP3 inflammasome, collagen I, MMP9, TGF-beta , caspase-1, caspase-3, Bax, & Bcl-2. (E) The protein semiquantification is shown for P2X7R, NLRP3 & caspase-1. (F) The protein semiquantification is shown for collagen I, MMP9 & TGF-beta . (G) The protein semiquantification is shown for caspase-3, Bax, & Bcl-2. (H) The percentages of TUNEL-positive cells are shown. (I) Representative images of TUNEL stained H9c2 myocytes. CON, H9c2 myocytes without any treatment; PA, H9c2 myocytes treated with 200 μM PA for 24 h; PA + A438079, H9c2 myocytes pretreated with A438079 for 12 h, & then treated with 200 μM PA for 24 h. ∗p < 0.05 versus the CON group, #p < 0.05 versus the HFD group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31681001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241613631.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - STZ-induced diabetes induces TXNIP expression & NLRP3 inflammasome activation following I/R 48. TXNIP expression was examined by IHC (a), representative blots (b), & quantitative analysis of Western blots for TXNIP (c), NLRP3 (d) & pro-caspase-1 & cleaved caspase-1 (e-f), & release of IL-1 beta & IL-18 by ELISA (g-h). The data in (c–h) are means ± SE (n = 5). ★P < 0.05 versus NS group; #P < 0.05 versus DS group; ▲P < 0.05 versus NI/R group; &P < 0.05 versus DI/R group. NS & DS: nondiabetic & STZ-induced diabetic rats were subjected to sham operation. NI/R & DI/R: nondiabetic & STZ-induced diabetic rats were subjected to 25 min ischemia followed by 48 h reperfusion. DI/R-RES: STZ-induced diabetic rats that underwent I/R were treated with RES (10 mg/kg, ip daily) for 7 consecutive days before renal ischemia-reperfusion. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27867451), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113521.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - Expression of Beclin 1 mRNA and protein in cells and tissues. (A) Beclin 1 mRNA expression level up-regulated in gastric cancer cell lines compared with normal gastric epithelial cells by reverse transcription-PCR. (B) Beclin 1 protein expression level up-regulated in gastric cancer cell lines compared with normal gastric epithelial cells by western blotting. (C) Beclin 1 mRNA expression is elevated in primary gastric tumors compared with paired gastric adjacent noncancerous tissues by reverse transcription-PCR. (D) Beclin 1 protein expression is elevated in primary gastric tumors compared with paired gastric adjacent noncancerous tissues by western blotting. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0045968) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Beclin-1-Antibody---BSA-Free-Western-Blot-NB500-249-img0018.jpg "Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - Expression of Beclin 1 mRNA and protein in cells and tissues. (A) Beclin 1 mRNA expression level up-regulated in gastric cancer cell lines compared with normal gastric epithelial cells by reverse transcription-PCR. (B) Beclin 1 protein expression level up-regulated in gastric cancer cell lines compared with normal gastric epithelial cells by western blotting. (C) Beclin 1 mRNA expression is elevated in primary gastric tumors compared with paired gastric adjacent noncancerous tissues by reverse transcription-PCR. (D) Beclin 1 protein expression is elevated in primary gastric tumors compared with paired gastric adjacent noncancerous tissues by western blotting. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0045968) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Beclin 1 Antibody - BSA Free [NB500-249] - Beclin 1/ATG6 Antibody [NB500-249] - Beclin 1 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/Beclin-1-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB500-249-img0013.jpg)
![Immunohistochemistry: Beclin 1 Antibody - BSA Free [NB500-249] - Detection of Beclin 1 (red) in Pheochromocytes of the Adrenal Medulla 40x.](http://images.novusbio.com/fullsize/Beclin-1-Antibody---BSA-Free-Immunohistochemistry-NB500-249-img0020.jpg)
![Flow Cytometry: Beclin 1 Antibody - BSA Free [NB500-249] - An intracellular stain was performed on U-87MG cells with Beclin 1 Antibody NB500-249 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/Beclin-1-Antibody---BSA-Free-Flow-Cytometry-NB500-249-img0024.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - Representative Western blot images and quantitative analyses of Beclin 1 from the left hemisphere of rat brains at different time points after SAH. Sample size is 36, n = 6 per group. Data were presented as mean +/- SD. F = 12.37 for Beclin 1. *P 0.05 versus TBI + vehicle group. beta -actin was used as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28429775), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-249_rabbit-polyclonal-beclin-1-antibody-31020241537194.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - AMPK knockout interrupts & decreases apoptosis in cochlea. (C) WB results show changes in autophagy-related proteins in cochleae of aging mice. There is a remarkable decline of mTOR signaling (Tg-B1 vs. AMPK+/−/Tg-B1, p 0.05 versus TBI + DMSO group. beta -actin was used as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28429775), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-249_rabbit-polyclonal-beclin-1-antibody-310202416161847.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - Inhibition of lysosomes leads to G1 arrest by inactivating cyclin E/CDK2 complex. (A) CQ treatment (10, 50, or 100 μM, 24 h) leads to cell cycle G1 arrest. Quantitation of different cell cycle stages in TM3 cells in the presence or absence of CQ. (B–D) EdU incorporation & mitotic index are reduced in CQ-treated TM3 cells. (B) Immunostaining of EdU (red) & DAPI (blue) in scramble control (CTL) or CQ treated TM3 cells. Quantitation of EdU incorporation (C) or mitotic index (D) in scramble control (CTL) or CQ-treated TM3 cells. These results are mean +/− SD from three independent experiments; more than 1000 cells were counted in each individual group. (E–G) CQ inhibited cyclin E1 expression & CDK2 activation. (E,F) Whole cell extracts of CQ-treated TM3 cells at the concentration of 10, 50, or 100 μM are analyzed by immunoblot with antibodies against Beclin1, cyclin D, cyclin A, cyclin E1, CDK2, phosphorylated CDK2 at Thr160 (pCDK2) & alpha -tubulin. (G) Quantitation of relative intensity of cyclin E & pCDK2 in (F). *P 50 cells were counted under a dissecting microscope. Image collected & cropped by CiteAb from the following publication (//jhoonline.biomedcentral.com/articles/10.1186/1756-8722-7-23), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-249_rabbit-polyclonal-beclin-1-antibody-31020241618261.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - Fucoxanthin activated autophagy after TBI.(A) Representative images of immunofluorescence for LC3 surrounding the injured cortex. LC3 punctate dots were observed in the cytoplasm by immunofluorescent staining of LC3 (red). Neuron cells & nuclei are labeled with NeuN (green) & DAPI (blue), respectively. Magnification: 40 x. Scale bar: 50 mm. (B) Mice brain tissues were collected 1 day after TBI in different groups, & the expression of LC3, Beclin-1 & p62 was measured by western blot. Fucoxanthin treatment significantly increased the level of LC3-II & Beclin-1 while decreasing the level of p62 after TBI. (C) 3-MA (400 nM) was injected i.c.v. 30 min before TBI. Mice were then subjected to TBI & treatment of fucoxanthin 30 min after TBI. Pretreatment with 3-MA significantly attenuated fucoxanthin-induced activation of autophagy & suppression of apoptosis & oxidative stress in the ipsilateral cortex. Data are presented as mean ± SEM, n = 6 per group; **p < 0.01, ***p < 0.001 versus sham group; #p < 0.05, ##p < 0.01 versus TBI + vehicle group; &&p < 0.01, &&&p < 0.001 versus TBI + fucoxanthin group. beta -actin was used as a loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28429775), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-249_rabbit-polyclonal-beclin-1-antibody-310202416171472.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - GABARAP interacts with AC3 via LIRs of AC3 in a ciliary expression‐dependent manner. A‐E) WB (A) & densitometric quantification of the expression of GABARAP (B), ATG5 (C), VPS34 (D), & Beclin1(E) in the hypothalami of AC3+/+, AC3−/−, & hAC3 mice (n = 3 mice per group). Actin served as the loading control. F) Representative IF co‐staining with AC3 & GABARAP antibodies in the VMHs of WT mice. F′) A higher magnification of the boxed region. Scale bars: F) 20 µm; F′) 5 µm. G) Representative images showing the expression levels of GABARAP & AC3 in the VMHs of VMH pIFT88‐AC3 KD mice & the controls. Scale bars: 20 µm. H) Schematic representation of GABARAP binding LIRs at aa488‐aa493 & aa958‐aa963 of AC3. I) Co‐IP analysis of GABARAP & AC3 (WT), AC3 (LIR1 Mut), or AC3 (LIR2 Mut). LgG served as the negative control. J) Pull‐down analysis of GABARAP & AC3. K) Co‐IP analysis of GABARAP & AC3 (WT), AC3 (296 Mut), or AC3 (465 Mut). LgG served as the negative control. L) Schematic representation of AC3 regulating GABARAP. Data represent the mean ± SEM; *p < 0.05 & **p < 0.01; one‐way ANOVA & Bonferroni pairwise comparisons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34783461), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-249_rabbit-polyclonal-beclin-1-antibody-310202416165618.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB500-249] - EMPA treatment enhanced autophagy in failing hearts. (A) Transmission electron microscopy (TEM) showed autophagosomes in the hearts. Red arrows point to autophagosomes. (B) EMPA activated autophagy pathway by inhibiting mTOR pathway. (C) RT-PCR results showed that the mRNA expression of Beclin1, Atg7 & LC3 were increased by EMPA treatment after TAC. Results are expressed as mean ± SEM, n = 5–7, *p < 0.05 vs. corresponding sham group, †p < 0.05 vs. corresponding TAC vehicle group. One-way ANOVA & Tukey post hoc test. EMPA, empagliflozin; SEM, standard error of the mean; TAC, transverse aortic constriction; AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin; Ulk, Unc-51 like autophagy activating kinase; Atg7, autophagy related 7; LC3, light chain 3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35647080), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb500-249_rabbit-polyclonal-beclin-1-antibody-31020241616566.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0014.jpg "Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis of RIP3 in HeLa cell lysate with RIPK3/RIP3 antibody [NBP1-77299] at (A) 1 and (B) 2 ug/mL. Observed molecular weight ~60 kDa. Theoretical molecular weight 53 kDa.")
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Mouse Cell lines. 15 ug of lysates per lane. Antibodies: [NBP1-77299], (0.5 ug/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Observed molecular weight ~50 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0022.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - Analysis using RIPK3/RIP3 antibody [NBP1-77299]. L929 cell line (mouse). 20 ug whole cell lysate. Primary antibody: 1:2000. Secondary antibody: 1:20000. Western blot image submitted by a verified customer review. Observed molecular weight ~57 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0024.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP1-77299] - C2C12 Cells. 15 ug of lysates per lane. Antibodies: RIPK3/RIP3 antibody [NBP1-77299], 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane 1: NBP1-77299, 0.1 ug/mL in the presence of peptide blocking. Lane 2: NBP1-77299, 0.1 ug/mL Lane 3: NBP1-77299, 0.2 ug/mL Lane 4: NBP1-77299, 0.5 ug/mL. Observed molecular weight ~55 kDa. Theoretical molecular weight 53 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP1-77299-img0021.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP1-77299] - Bone-marrow-derived macrophages exhibit significant reduction in RIPK3 levels in Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre mice. (A,B) BMDMs were isolated, differentiated on chamber slides for 7 days, immunostained for macrophage markers CD68 (red; A) & CD11b (pink; B), & co-stained for nuclei (Hoechst; blue). All cells from seven separate BMDM isolations were positive for these markers (n=7). (C) A phagocytosis assay was performed on BMDMs with fluorescent polystyrene beads. Phagocytic cells display TRITC+/Hoechst+ signal, & 85% of cells from two separate BMDM isolations were double positive (n=2). (D-F) Protein or RNA was collected from control, Ripk3 delta Global, Ripk3 delta MΦ-Cre & Ripk3 delta EC-Cre BMDMs. RNA was converted to cDNA & analyzed by qPCR for Ripk3 levels (D). Protein lysates were immunoblotted to identify CD11b, RIPK3 & beta -actin (loading control) (E) & quantified (F). (G) RNA from control & Ripk3 delta Global BMDMs was converted to cDNA & analyzed by qPCR for Ripk3-Exon 10 levels. For panels D,F,G, each dot represents a BMDM isolation from an individual animal. Statistics for panels D & F were calculated using one-way ANOVA with Dunnett's multiple comparisons test. Overall ANOVA P-values (prior to the post hoc tests) are 0.0002 (D) & 76%. Values are expressed as means +/- SEM; * p 76%. Values are expressed as means +/- SEM; * p < 0.05 versus WT group; #p < 0.05 versus WT-I/R group, (n = 6/group). (D) Graph showing increases in the levels of serum creatine in WT mice after renal I/R compared to sham-operated animals. However, in RIP3−/− mice, the level of serum creatine was reduced when compared to littermate WT mice after renal I/R. Note that there was no difference in the levels of serum creatine between WT and RIP3−/− sham mice. Values are expressed as means +/- SEM; * p < 0.05 versus WT-Sham group, respectively; #p < 0.05 versus WT-I/R group (n = 6/group). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35741025), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77299_rabbit-polyclonal-ripk3-rip3-antibody-knockout-validated-132202618215124.jpg)
![Simple Western: Beclin 1 Antibody [NB110-87318] - Lane view shows a specific band for Beclin in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Simple-Western-NB110-87318-img0019.jpg "Simple Western: Beclin 1 Antibody [NB110-87318] - Lane view shows a specific band for Beclin in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Western Blot: Beclin 1 Antibody [NB110-87318] - Total protein from human HeLa and mouse Neuro2A cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-Beclin-1 in blocking buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Western-Blot-NB110-87318-img0012.jpg)
![Immunohistochemistry-Paraffin: Beclin 1 Antibody [NB110-87318] - Analysis of a FFPE tissue section of human breast cancer using Beclin 1 antibody (Lot 71917) at 1:300 dilution. The primary antibody bound to Beclin 1 antigen in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. Cytoplasmic staining can be seen in the cancer as well as the stromal cells. The signal was strongest in a subset of stromal cells which appears to be the cancer associated fibroblasts.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Immunohistochemistry-Paraffin-NB110-87318-img0017.jpg)
![Western Blot: Beclin 1 Antibody [NB110-87318] - Basal levels of autophagy in the hypothalamus of BACHD mice. The expression levels of selected autophagy markers were analyzed by Western blot in hypothalamic tissue from BACHD mice at 2, 6 and 12 months of age and compared with gender- and age-matched controls (n=3-6/group). The data showed a substantial maintenance of the autophagy flux, despite the presence of a metabolic phenotype in the BACHD mice already at early time points. The data in the graphs are expressed as mean +/- SEM, relative to the 2 months wt controls. The Western blots are representative of one sample for each group. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0083050), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Western-Blot-NB110-87318-img0021.jpg)
![Immunocytochemistry/Immunofluorescence: Beclin 1 Antibody [NB110-87318] - Beclin 1/ATG6 Antibody [NB110-87318] - Beclin1 antibody was tested in HeLa cells with FITC (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-87318-img0020.jpg)
![Immunohistochemistry-Paraffin: Beclin 1 Antibody [NB110-87318] - Analysis of a FFPE tissue section of human breast cancer using Beclin 1 antibody (Lot F4) at 1:300 dilution. The primary antibody bound to Beclin 1 antigen in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. Cytoplasmic staining can be seen in the cancer as well as the stromal cells. The signal was strongest in a subset of stromal cells which appears to be the cancer associated fibroblasts.](http://images.novusbio.com/fullsize/Beclin-1-Antibody-Immunohistochemistry-Paraffin-NB110-87318-img0016.jpg)
![Western Blot: Beclin 1 Antibody [NB110-87318] - Image from verified customer review.](http://images.novusbio.com/fullsize/Beclin-1-ATG6-Antibody-Western-Blot-NB110-87318-img0010.jpg)
![Immunohistochemistry: Beclin 1/ATG6 Antibody [NB110-87318] - Staining of normal breast tissue.](http://images.novusbio.com/fullsize/Beclin-1-ATG6-Antibody-Immunohistochemistry-NB110-87318-img0006.jpg)
![Western Blot: Beclin 1 Antibody - BSA Free [NB110-87318] - Maintenance of basal levels of autophagy in mice overexpressing htt fragments in the hypothalamus.The expression levels of selected autophagy markers were analyzed by Western blot in mice bilaterally injected with rAAV5-htt853-18Q or rAAV5-htt853-79Q & compared to uninjected controls 8 weeks post injection (n = 6–7/group). The data displayed maintenance of the autophagy flux, despite the presence of a clear metabolic phenotype in the injected mice. The data in the graphs are expressed as mean ± SEM relative to the uninjected controls. The Western blots are representative of one sample for each group. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0083050), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-87318_rabbit-polyclonal-beclin-1-antibody-31020241539256.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and LAMP2 knockout (KO) HeLa cell line. PVDF membrane was probed with Mouse Anti-Human LAMP-2/CD107b (H4B4) Monoclonal Antibody (Catalog # NBP2-22217) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LAMP-2/CD107b at approximately 100 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Knockout-Validated-NBP2-22217-img0016.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lysates of HeLa human cervical epithelial carcinoma parental cell line and LAMP2 knockout (KO) HeLa cell line. PVDF membrane was probed with Mouse Anti-Human LAMP-2/CD107b (H4B4) Monoclonal Antibody (Catalog # NBP2-22217) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog #HAF008). Specific band was detected for LAMP-2/CD107b at approximately 100 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Immunofluorescence: [Alexa Fluor® 647] [NBP2-22217AF647] - T98G glioblastoma cells grown on #1.5 coverglass stained with a conjugated LAMP-2/CD107b (H4B4)AF647 antibody, counterstained with DAPI. Cathepsin D (green) staining also visible. This image was submitted via customer Review. Image using the Alexa Fluor 647 form of this antibody.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Immunocytochemistry-Immunofluorescence-NBP2-22217-img0015.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Analysis of LAMP-2/CD107b expression in Whole Cell Lysates: 2) HeLa, 3) Jurkat, 4) U937, 5) HepG2, Tissue Extracts: 6) Human kidney, 7) Human lung, 8) Human liver, and 9) Human placenta.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Western-Blot-NBP2-22217-img0003.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Staining of LAMP-2/CD107b in human liver using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Immunohistochemistry-Paraffin-NBP2-22217-img0001.jpg)
![Flow Cytometry: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - An intracellular stain was performed on U937 cells with HGF LAMP-2/CD107b [H4B4] Antibody NBP2-22217AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Flow-Cytometry-NBP2-22217-img0017.jpg)
![Simple Western: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Lane view shows a specific band for LAMP-2/CD107b in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Simple-Western-NBP2-22217-img0005.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Localization of TMEM135 to the mitochondria. The mitochondrial fraction isolated from the WT mouse brain show TMEM135 signals by immunoblotting. Following proteins were used as organelle markers: MFN2-mitochondria; LAMP2-lysosome; Lamin B1- nucleus; PDI- endoplasmic reticulum (ER). Image collected and cropped by CiteAb from the following publication (//elifesciences.org/articles/19264), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Western-Blot-NBP2-22217-img0019.jpg)
![Western Blot: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Representative pictures of effect of I/R on DNA damage, cell survival, and inflammation. Western blot analysis expression level of Cathepsin B (*P < 0.05) in total protein extract from RVA of I/R treated vs. control group. Image collected and cropped by CiteAb from the following publication (//www.frontiersin.org/article/10.3389/fphar.2018.01034/full), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Western-Blot-NBP2-22217-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-LAMP-2/CD107b [NBP2-22217] at a 1:100 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Immunocytochemistry-Immunofluorescence-NBP2-22217-img0008.jpg)
![Flow Cytometry: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Intracellular flow cytometric staining of 1 x 10^6 HEK-293 cells using anti-LAMP-2/CD107b (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-Flow-Cytometry-NBP2-22217-img0004.jpg)
![ELISA: LAMP-2/CD107b Antibody (H4B4) [NBP2-22217] - Anti-LAMP-2/CD107b was used to assess lysates from human SVG-A cells via ELISA, by loading the indicated mass of total protein per well. Antibodies tested were diluted 1:250, and used in conjunction with an HRP-conjugated secondary antibody. Signal was detected by luminescence. Image from verified customer review.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-H4B4-ELISA-NBP2-22217-img0014.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0011.jpg "Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Staining of NALP3 in K562 cells with NALP3 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0010.jpg)
![Immunohistochemistry-Paraffin: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in mouse lung tissue using anti-NALP3 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP1-77080-img0003.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in K562 cell lysate with NALP3 antibody at 1 ug/mL (A) in the absence and (B) in the presence of blocking peptide.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0009.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. Representative image of immunofluorescent staining of NLRP3 related genes in corneal and conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3 Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0012.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. (A) Representative image of immunofluorescent staining of NLRP3 related genes in corneal & conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). (B,C) qRT-PCR showed the mRNA levels of NLRP3 related genes in conjunctiva & cornea (four corneas/conjunctivas were mixed as a sample). Data was shown as mean ± SEM. *p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241535675.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of exogenous rHMGB1 significantly promoted the mRNA & protein production of NLRP3 (a, c) & ASC (e, g) & activation of caspase-1 (i). Thus, the intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed the production of NLRP3 (b, d) & ASC (f, h) & activation of caspase-1 (j). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415345338.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Co-immunoprecipitation assay: Figure showing interaction of NLRP3, NLRC4 & NAIP with ASC during CFT073 infection in THP-1m. Cytoplasmic extracts of THP-1m infected with or without CFT073, 6 h post stimulation were subjected to IP & WB by various antibodies (ASC, NLRP3, NLRC4, & NAIP) as described in material & methods. Cytoplasmic extract used as input was subjected to check NLRP3, ASC, NLRC4 & NAIP expression as shown in figure. ASC antibody was used to co-immunoprecipitate the complex from cytoplasmic extracts & then immunoblotted to detect NLRP3, NLRC4 & NAIP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31551961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415371971.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 regulated the activation of NLRP3, rather than the activation of caspase-8, via NF-kappa B pathway. a, b NF-kappa B was activated in ischemic retina at the early stage after reperfusion. c, d Intraocular injection rHMGB1 or GA could promote or suppress the production of phosphor-NF-kappa B p65. e, f Intravitreal injection of NF-kappa B p65 inhibitor, JSH-23, significantly reduced the activation of NLRP3 & decreased the processing of IL-1 beta , g rather than caspase-8. However, intravitreal injection of caspase-8 inhibitor, Z-IETD-fmk, decreased the production of phosphor-NF-kappa B p65, obviously (h). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415291993.jpg)
![Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Immunohistochemistry-Paraffin-NBP2-24588-img0004.jpg "Immunohistochemistry-Paraffin: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 Antibody [NBP2-24588]. Human pancreas probed with RIPK3/RIP3 antibody at 10 ug/ml.")
![<b>Biological Strategies Validation. </b>Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Representative western blot analysis of RIP1, RIPK3/RIP3, and beta-actin in WI-38 NCs and IR-SCs 24 h after incubation with Veh or 10 uM PL. A cell lysate of etoposide-treated Jurkat cells was used as a positive control. Image collected and cropped by CiteAb from the following publication (//www.aging-us.com/article/101100/text) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP2-24588-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: RIPK3/RIP3 Antibody [NBP2-24588] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with RIPK3/RIP3 Antibody [NBP2-24588] at a 1:200 dilution overnight at 4C and detected with DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used at a 1:1000 dilution as a co-stain and detected with DyLight 550 (Red) at a 1:500 dilution. Nuclei were detected with DAPI (Blue) at 2.0ug/ml in 1X PBS. Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24588-img0003.jpg)
![Western Blot: RIPK3/RIP3 Antibody [NBP2-24588] - Analysis of RIP3 using polyclonal RIPK3/RIP3 antibody [NBP2-24588]. Human tissue blot probed with 5 ug/ml of RIP3 antibody: 1) brain, 2) heart, 3) small intestine, 4) kidney, 5) liver, 6) lung, 7) skeletal muscle, 8) stomach, 9) spleen, 10) ovary, 11) testis, 12) placenta probed at 5 ug/ml, 13) Ramos cell lysate probed at 7 ug/ml. Theoretical molecular weight 56.7 kDa.](http://images.novusbio.com/fullsize/RIPK3-RIP3-Antibody-Western-Blot-NBP2-24588-img0005.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - HOIP limits the activity of TRAIL‐induced apoptosis‐ & necroptosis‐mediating signalling complexesControl & HOIP KO HeLa cells were treated with FLAG‐lz‐TRAIL (500 ng/ml) for the indicated times. The TRAIL complex I was immunoprecipitated via anti‐FLAG beads. Complex II was isolated by immunoprecipitating caspase‐8 from complex I‐depleted lysates. Western blot was performed using the indicated antibodies. * indicates unspecific bands.WT & HOIP‐deficient TNF KO MEFs, pre‐treated for 1 h with zVAD, were stimulated with iz‐TRAIL (1 μg/ml) for the indicated times. FADD‐containing complexes were immunoprecipitated & analysed by Western blot.Data information: See also Fig EV2. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24588_rabbit-polyclonal-ripk3-rip3-antibody-31020241534394.jpg)
![Western Blot: RIPK3/RIP3 Antibody - BSA Free [NBP2-24588] - The catalytic activity of HOIP contributes to preventing TRAIL‐induced apoptosis but is dispensable for preventing necroptosisLysates from control or HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD and/or Nec‐1s for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 5; mean ± SEM). *P < 0.05, **P < 0.01; statistics performed using ANOVA.Control & HOIP KO K562 cells reconstituted w/ empty vector, HOIP WT or HOIP C885S treated w/ iz‐TRAIL (100 ng/ml) for the indicated times. Lysates analysed w/ the indicated antibodies.Lysates from TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S analysed by WB.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD & Nec‐1s for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 4; mean ± SEM). *P < 0.05, ***P < 0.001; statistics performed using ANOVA.TNF KO HOIP KO MEFs reconstituted w/ empty vector, pre‐treated w/ zVAD and/or the RIPK3 inhibitor GSK'872 for 1 h as indicated, treated w/ iz‐TRAIL (1 μg/ml) for 24 h. Percentage of cell death determined by flow cytometry after PI labelling (n = 3; mean ± SEM). *P < 0.05; statistics performed using t‐test.TNF KO HOIP KO MEFs reconstituted w/ empty vector, HOIP WT or HOIP C885S, pre‐treated w/ zVAD for 1 h, treated w/ iz‐TRAIL (1 μg/ml) for the indicated times. FADD‐containing complexes immunoprecipitated & analysed by WB. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28258062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-24588_rabbit-polyclonal-ripk3-rip3-antibody-310202416114733.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0012.jpg "Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.")
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Normal deparaffinized Human placenta tissue tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0015.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human prostate carcinoma tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0016.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 25ug of NRK cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0017.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Validation of subcellular fractionation and immunocytochemistry. RLC proteins are present at ER microsomes. Lysates from 7 DIV cortical neurons were subjected to differential centrifugation to isolate nuclear pellet (P1), postnuclear supernatant (PNS), mitochondrial pellet (P2), and ER microsomal pellet (P3), as depicted in the graphic on the right. Image collected and cropped by CiteAb from the following publication (www.onlinelibrary.wiley.com/doi/10.15252/embr.201744853) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:100 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody and nuclei with DAPI (blue) is shown.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0019.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 10 ug of HeLa (left panel), NIH/3T3 (middle panel) and NRK (right panel) whole cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b (green) in NIH/3T3 cells.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0013.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human tonsils were stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0014.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Exposure of rat primary microglial cells (rPMs) to combined antiretroviral therapy (cART) cocktail resulted in impaired lysosomal function. rPMs were seeded into six-well plates & treated with cART (5 µM each of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), & dolutegravir (DTG)) for the indicated time periods. (A,B) Exposure of microglia to cART resulted in a significant decrease in expression of lysosomal-associated membrane protein 2 (LAMP2) at 6 to 24 h post-treatment. (C) Representative bar graph showing cART-mediated significantly increased lysosomal membrane permeabilization (LMP) (24 h). (D,E) Microglia exposed to cART demonstrated a significant decrease in levels of mature cathepsin D (mCTSD) at 24 h post-treatment. (F) Representative bar graph showing exposure of cART significantly reduced the CTSD activity in rPMs (24 h). (G) Representative bar graph showing cART-mediated increased lysosomal pH in rPMs. (H,I) Acridine orange staining showing increased green color & reduced red color in cART-treated rPMs. H2O2 was used as a positive control for lysosome damage. Data is from three independent experiments. Actin beta (ACTB) served as a protein loading control for western blots. Data are expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; N.S., non-significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-310202416175213.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - HSPA overexpression abrogated cART-mediated impairment of lysosomal function. Control rPMs & heat shock protein family A (HSPA) overexpressing rPMs were seeded into six-well plates subjected to various treatments for 24 h. Protein homogenates were prepared for the detection of the indicated molecules. (A,B) Representative western blots showing overexpressing HSPA in rPMs reversed cART-mediated downregulation of LAMP2 & mCTSD expression levels. (C) Representative bar graph showing overexpression of HSPA in rPMs protected lysosomal pH. (D,E) Representative bar graphs showing HSPA protected LMP (D), & CTSD activity (E) in cART-treated rPMs. For all western blots, ACTB served as a protein loading control. Data is from three independent experiments & is expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; #, p < 0.05 vs. cART. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-31020241618933.jpg)
![Immunohistochemistry: Defensin alpha 5 Antibody (8C8) [NB110-60002] - Human skeletal muscle myocytes showing moderate nuclear and faint cytoplasmic staining.](http://images.novusbio.com/fullsize/Defensin-alpha-5-Antibody-8C8-Immunohistochemistry-NB110-60002-img0003.jpg "Immunohistochemistry: Defensin alpha 5 Antibody (8C8) [NB110-60002] - Human skeletal muscle myocytes showing moderate nuclear and faint cytoplasmic staining.")
![Flow Cytometry: Defensin alpha 5 Antibody (8C8) [NB110-60002] - Intracellular flow cytometric staining of 1 x 10^6 MCF-7 cells using Defensin alpha 5 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Defensin-alpha-5-Antibody-8C8-Flow-Cytometry-NB110-60002-img0004.jpg)
![TRAF6 Inhibitor Peptide Set [NBP2-26506] - The TRAF6 inhibitory peptide inhibits osteoclast ifferentiation: RAW264.7 cells were plated on 24-well plates and stimulated with RANKL and M-CSF and incubated in the presence of different concentrations of control peptide (PTD) or the TRAF6. The TRAF6 at the concentration above 30 uM suppressed osteoclast differentiation.](http://images.novusbio.com/fullsize/TRAF6-Inhibitor-Peptide-Set-NBP2-26506-img0002.jpg "TRAF6 Inhibitor Peptide Set [NBP2-26506] - The TRAF6 inhibitory peptide inhibits osteoclast ifferentiation: RAW264.7 cells were plated on 24-well plates and stimulated with RANKL and M-CSF and incubated in the presence of different concentrations of control peptide (PTD) or the TRAF6. The TRAF6 at the concentration above 30 uM suppressed osteoclast differentiation.")
![Simple Western: VPS34 Antibody [NB110-87320] - Simple Western lane view shows a specific band for VPS34 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/VPS34-Antibody-Simple-Western-NB110-87320-img0006.jpg "Simple Western: VPS34 Antibody [NB110-87320] - Simple Western lane view shows a specific band for VPS34 in 0.5 mg/ml of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![<b>Genetic Strategies Validation. </b>Western Blot: VPS34 Antibody [NB110-87320] - ATG7 depleted SKBR3 cells show increased sensitivity to ATRA and the RARalpha agonist AM580. RARalpha , ATG5 and VPS34 Western blot analysis of control and the respective SKBR3 knockdown cells. GAPDH was used as a loading control. Image collected and cropped by CiteAb from the following publication (), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/VPS34-Antibody-Knockdown-Validated-NB110-87320-img0007.jpg)
![Western Blot: VPS34 Antibody [NB110-87320] - HepG2 whole cell lysates.](http://images.novusbio.com/fullsize/VPS34-Antibody-Western-Blot-NB110-87320-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: VPS34 Antibody [NB110-87320] - VPS34 antibody was tested at 1:200 in HeLa cells with FITC (green). Nuclei (Blue) were counterstained with Dapi (blue).](http://images.novusbio.com/fullsize/VPS34-Antibody-Immunocytochemistry-Immunofluorescence-NB110-87320-img0005.jpg)
![Western Blot: VPS34 Antibody [NB110-87320] - Celastrol regulates autophagy- & mitophagy-related gene expressions in neurons. SH-SY5Y cells treated with 0.1–1 μM celastrol for 4 h. (A) Real-time quantitative PCR results show that 1 μM celastrol treatment for 4 h enhanced mRNA expressions of phagophore induction genes Beclin 1 & Ambra1, phagophore elongation genes Atg7 & Atg12, & vacuole formation genes LC3A & Atg4B. (B) Western blot results of SH-SY5Y treated with 100–500 nM celastrol show celastrol (500 nM) increased in protein expressions of Beclin 1 & Vps34 (phagophore induction), Atg7 (phagophore elongation), LC3-II (vacuole formation), DJ-1, & PINK1 (mitophagy). Celastrol (500 nM) suppressed LRRK2 expression. (C) MPTP (10 mg/kg/day for 3 days, i.p.) but not celastrol (3 mg/kg/day for 3 days, i.p.) caused dopaminergic nerve terminal degeneration (tyrosine hydroxylase↓) & mitophagy inactivation (DJ-1↓ & PINK1↓) in the striatum of mice as compared to saline control. Celastrol cotreatment with MPTP reversed it as compared to MPTP. Data are given as the mean ± SEM (n = 3–5). p-value was determined using the Kruskal–Wallis test followed by Dunn’s multiple comparison post hoc test. * p < 0.05 compared with controls. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31906147), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-87320_rabbit-polyclonal-vps34-antibody-310202416205164.jpg)
![Western Blot: NOD1 Antibody [NB100-56152] - Evo-induced apoptosis of HCC cells occurred via the NOD1 pathway in vivo. (A,B) The mice treated with or without 10 mg/kg of Evo. Levels of proteins in the NOD1 pathway in tumor tissues were detected by the Western blot method. Image collected and cropped by Citeab from the following publication (Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway. Int J Mol Sci (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NOD1-Antibody-Western-Blot-NB100-56152-img0003.jpg "<b>Orthogonal Strategies Validation. </b>Western Blot: NOD1 Antibody [NB100-56152] - Evo-induced apoptosis of HCC cells occurred via the NOD1 pathway in vivo. (A,B) The mice treated with or without 10 mg/kg of Evo. Levels of proteins in the NOD1 pathway in tumor tissues were detected by the Western blot method. Image collected and cropped by Citeab from the following publication (Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway. Int J Mol Sci (2018)) licensed under a CC-BY license.")
![<b>Biological Strategies Validation and Orthogonal Strategies Validation.</b>Immunocytochemistry/Immunofluorescence: NOD1 Antibody [NB100-56152] - Immunocytochemistry/Immunofluorescence: NOD1 Antibody [NB100-56152] - Representative images from the immunofluorescence method (x400). HepG2 and SMMC-7721 cells were incubated with or without Evo (0, 0.5, and 1 uM) for 24 h to detect levels of NOD1 and p-P65. Values are means and standard errors of three separate experiments (* p < 0.05 and ** p < 0.01 versus control). Image collected and cropped by Citeab from the following publication (Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway. Int J Mol Sci (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NOD1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56152-img0005.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: NOD1 Antibody [NB100-56152] - Evo-induced apoptosis of HCC cells occurred via the NOD1 pathway in vivo. (A,B) The mice treated with or without 10 mg/kg of Evo. Levels of proteins in the NOD1 pathway in tumor tissues were detected by the Western blot method. Image collected and cropped by Citeab from the following publication (Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway. Int J Mol Sci (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NOD1-Antibody-Western-Blot-NB100-56152-img0004.jpg)
![Immunohistochemistry-Paraffin: NOD1 Antibody [NB100-56152] - Section of human sebaceous gland (A) and colon (B) stained for NOD1 expression using NB100-56152 at 1:2000. Hematoxylin counterstain. 10X magnification.](http://images.novusbio.com/fullsize/NOD1-Antibody-Immunohistochemistry-Paraffin-NB100-56152-img0002.jpg)
![Immunohistochemistry-Paraffin: NOD1 Antibody [NB100-56152] - Sections of human colon (A, A1) and pancreas (B, B1) stained for NOD1 expression using a DAB chromogen and Hematoxylin counterstain. Magnification: A (20X), A1 (40X). B (10X), B1 (40X).](http://images.novusbio.com/fullsize/NOD1-Antibody-Immunohistochemistry-Paraffin-NB100-56152-img0001.jpg)
![Western Blot: NOD1 Antibody [NB100-56152] - Evo induces apoptotic cell death of HepG2 & SMMC-7721 cells via the NOD1-mediated apoptotic pathway in vitro. HepG2 & SMMC-7721 cells were treated with 10 µg/mL IE-DAP for 2 h before exposure to 1 µM Evo. Apoptosis (A), cycle arrest (B), apoptosis-related protein levels (C) & the proteins’ levels of NOD1 pathway (D) in treated & untreated cells were measured by 5-ethynyl-2′-deoxyuridine (EdU) (×40), cellular propidium iodide (PI) fluorescence & Western blot methods. The percentage of proliferating cells (EdU+) was quantitated using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Values are means & standard errors of three separate experiments (* p < 0.05 & ** p < 0.01 versus control, #p < 0.05 & ##p < 0.01 versus Evo). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30384473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56152_rabbit-polyclonal-nod1-antibody-31020241534319.jpg)
![Western Blot: NOD1 Antibody [NB100-56152] - Evo-induced apoptosis of HCC cells occurred via the NOD1 pathway in vivo. (A,B) The mice treated with or without 10 mg/kg of Evo. Levels of proteins in the NOD1 pathway in tumor tissues were detected by the Western blot method. (C) Representative images from the immunofluorescence method. Expression of NOD1 (×400) & p-P65 (×200) in tumor tissues was analyzed by the immunofluorescence method. Values are means & standard errors of five separate experiments (* p < 0.05 & ** p < 0.01 versus control). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30384473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56152_rabbit-polyclonal-nod1-antibody-310202415175228.jpg)
![Western Blot: NOD1 Antibody [NB100-56152] - Evo decreases expression of NOD1 resulting in suppression of nuclear factor-kappa B (NF-kappa B) & mitogen-activated protein kinase (MAPK) activation in vitro. (A) Expression of NOD1 in normal hepatocyte HL-7702, HepG2, & SMMC-7721 cells were detected by qRT-PCR & Western blot assays. (B) HepG2 & SMMC-7721 cells were incubated with 1 µM Evo for 0, 3, 6, & 12 h. The Western blot assay was performed to detect levels of proteins in the NOD1 pathway. (C) Representative images from the immunofluorescence method (×400). HepG2 & SMMC-7721 cells were incubated with or without Evo (0, 0.5, & 1 µM) for 24 h to detect levels of NOD1 & p-P65. Values are means & standard errors of three separate experiments (* p < 0.05 & ** p < 0.01 versus control). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30384473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56152_rabbit-polyclonal-nod1-antibody-310202415293347.jpg)